Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose furmonertinib first-line study in EGFR-mutant NSCLC with co-occurring genetic alterations
ChiCTR2400092676Phase 2Not yet recruiting
- Sponsor
- Anqing Municipal Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Anqing Municipal Hospital. Primary endpoint: Progression-free survival. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400092676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092676.